Nanotechnology Applications in Breast Cancer Immunotherapy.

Area of Science:

• Oncology
• Immunology
• Nanotechnology

Background:

• Next-generation cancer treatments aim to target cancer cells, train immune cells, and modulate the tumor microenvironment for robust anti-cancer responses.
• Nanotechnology offers potential solutions for codelivering multiple therapeutics to cancer and immune cells, addressing challenges in current treatments.
• Immune checkpoint inhibitors (ICIs) show success in some cancers but have low response rates in breast cancer due to factors like low T-cell infiltration and an immunosuppressive tumor microenvironment (TME).

Purpose of the Study:

• To highlight recent advances in nanoimmunotherapeutic development for cancer treatment, with a specific focus on breast cancer.
• To discuss the role of nanoparticles in enhancing anti-cancer T-cell responses and manipulating the TME.
• To explore the outlook, challenges, and future directions of nanoimmunotherapeutics.

Main Methods:

• Utilizing nanoparticles for the codelivery of immune checkpoint inhibitors (ICIs), bispecific antibodies, cytokines, and agents inducing immunogenic cancer cell death (ICD).
• Employing nanoparticles to modulate immunosuppressive components within the tumor microenvironment (TME), including myeloid cells, macrophages, dendritic cells, and fibroblasts.
• Reviewing and synthesizing recent research on nanoimmunotherapeutics in the context of breast cancer treatment.

Main Results:

• Nanoparticles can enhance anti-cancer T-cell responses by delivering various therapeutic agents.
• Nanoparticles are effective in manipulating the immunosuppressive tumor microenvironment (TME) to improve T-cell activities.
• Nanoimmunotherapeutics show promise in overcoming the limitations of current breast cancer treatments, particularly the low response rates to ICIs.

Conclusions:

• Nanotechnology-based approaches are crucial for developing advanced cancer immunotherapies that can effectively target cancer cells and modulate the immune system.
• Nanoimmunotherapeutics offer a promising strategy to improve treatment efficacy in breast cancer by enhancing T-cell infiltration and overcoming the immunosuppressive TME.
• Further research and development in nanoimmunotherapeutics are essential to address existing challenges and unlock their full potential for durable cancer treatment.